Madrigal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Madrigal Pharmaceuticals Inc MDGL.OQ reported a quarterly adjusted loss of $1.90​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-7.10. The mean expectation of fifteen analysts for the quarter was for a loss of $3.64 per share. Wall Street expected results to range from $-5.15 to $-2.35 per share.

• Revenue rose 1,353.8% to $212.80 million from a year ago; analysts expected $162.32 million.

• Madrigal Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.90​.

• The company reported a quarterly loss of $42.28 million.

• Madrigal Pharmaceuticals Inc shares had risen by 3.1% this quarter and gained 1.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $417.50, about 25.2% above its last closing price of $312.11

This summary was machine generated from LSEG data August 5 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)